PuSH - Publication Server of Helmholtz Zentrum München: Considering insulin secretory capacity as measured by a fasting c-peptide/glucose ratio in selecting glucose-lowering medications.

Navigation

Home

Deutsch

Research

Advanced Search

Browse by ...

... Journal

... Publication Type

... Research Data

... Publication Year

Publication overview

Support & Contact

Contact persons

Help

Data protection

Fritsche, A. ; Heni, M. ; Peter, A. ; Gallwitz, B. ; Kellerer, M.* ; Birkenfeld, A.L. ; Häring, H.-U. ; Wagner, R.

Considering insulin secretory capacity as measured by a fasting c-peptide/glucose ratio in selecting glucose-lowering medications.

Exp. Clin. Endocrinol. Diabet. 130, 200-204 (2022)

Publ. Version/Full Text

DOI

PMC

	Open Access Gold (Paid Option)

Abstract
Metrics
Extra information

Type 2 diabetes mellitus is a heterogeneous disease. Recently introduced new subclassifications promise more efficacious, tailored treatments which could complement current guidelines. In the differentiation of the new diabetes subphenotypes, assessment of insulin secretion is one of the essential components. Based on a large number of insulin secretion measurements, we propose fasting C-peptide/glucose ratio (CGR) as an adequate and practicable estimate of insulin secretion. CGR discriminates insulin deficiency from insulin hypersecretion. We suggest using insulin secretion, determined from CGR, as an essential input for therapeutic decisions at the beginning or modification of diabetes treatment. Furthermore, we propose 3 practical steps to guide decisions in the subtype-specific therapy of diabetes mellitus. The first step consists of detecting insulin deficiency indicated by a low CGR with the need for immediate insulin therapy. The second step is related to high CGR and aims at lowering cardiovascular risk associated with diabetes. The third step is the consideration of a de-escalation of glucose-lowering therapy in individuals with mild diabetes subphenotypes.

Altmetric

Additional Metrics?

[➜Log in]